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ALK-negative anaplastic large cell lymphoma (ALK-negative ALCL) is a heterogeneous disease 
with very disparate outcomes. Molecular studies have identified chromosomal 
rearrangements involving the DUSP22-IRF4 locus on 6p25.3 (DUSP22 rearrangements) as a 
favourable prognostic factor, associated with complete remission after first treatment thereby 
suggesting that this subgroup of patients may not gain additional benefit from autologous 
stem cell transplantation in first remission(1-3). Recognition of these cases is critical, and we 
therefore aimed to study in greater detail the histological and immunophenotypic features of 
DUSP22-rearranged ALK-negative ALCLs. 
After approval by the Institutional Review Board of the Hospital Universitario Marqués de 
Valdecilla and the Fundación Jiménez Díaz (Spain), we collected 91 cases with a diagnosis of 
systemic or primary cutaneous ALCL made at the participating institutions. Clinical data were 
retrieved and cases were reviewed by three independent pathologists (AO, SMRP, MAP), using 
hematoxylin and eosin stains. Immunohistochemistry was performed using a panel of 
antibodies against ALK, CD3, CD4, CD8,  granzyme B, MUM1, perforin, P-STAT3 (D3A7, 1/400 
Cell Signaling), TIA1, P-STAT5, TCR-βF1, P63, STAT3 (supplementary data). Of 91 evaluated 
cases, 18 were primary cutaneous ALCLs (pcALCLs) and 73 cases were systemic ALCLs (19 were 
ALK-positive ALCLs). ALK-positive cases were not further considered for the study. Only 31 
cases were eligible for further study due to tissue scarcity, including 22 ALK- ALCL and 9 
pcALCLs. FISH analyses were performed on these cases using an IRF4-DUSP22 (6p25.3) break-
apart probe (KBI-10613; Kreatech, Leica, Spain) following standard procedures(4, 5). Cytotoxic 
markers, pSTAT3, p63 and MUM1 expression were evaluated as described in the 
supplementary data. Associations of genetic and immunohistochemical subgroups with OS and 
PFS were assessed using Kaplan-Meier curves. Differences between genetic subgroups in 
patient characteristics, tumour phenotype and other clinical factors were assessed using the 
chi-square test and Wilcoxon rank-sum test, as appropriate. 
Of the 31 cases tested for p63 rearrangements, 1 case (1/31, 3.2%) was positive, 26 were 
negative (26/31, 83.8%), and 3 showed gains of p63 (3/31, 9.7%). One case (1/22, 4.5%) had 
DUSP22 gains, and another case had DUSP22 amplification. Twenty-five cases (25/31, 80.6%) 
were classified as triple-negative ALCLs, and six cases had DUSP22 rearrangements, including 4 
ALK-negative ALCLs (4/22, 18.2%), and 2 pcALCLs (2/9, 22.2%), representing the study cohort. 
Demographic and clinical characteristics of DUSP22-rearranged cases are shown in Table 1. The 
six patients were aged from 39 to 65 years at presentation (mean, 56 years), with a 
predominance of males (2M:1F). In one of the pcALCL cases (case 5), the lesions were 
restricted to a single body area – the cheek; the site location was not available for case 6. 
Systemic DUSP22-rearranged cases exhibited a high clinical stage at presentation, with low 
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ECOG performance status, IPI and PIT indices. One patient had bone marrow involvement at 
diagnosis and high LDH levels. Two patients received CHOP-based treatment regimens, and 
another received radiotherapy. All three patients achieved complete remission according to 
the available clinical information. Only the patient receiving radiotherapy as front-line 
treatment relapsed 9 months after initial treatment. None of them underwent stem-cell 
transplantation. After a median follow-up of 55 months, all four patients with systemic 
DUSP22-rearranged ALCL were alive without disease. Patients with pcALCL were treated by 
excision, and there was no recurrence or progression during follow-up (Table 1). Median 
follow-up time from diagnosis for systemic ALCL patients who were still alive was 43 months 
(range, 3 to 126 months).  
Consistently with the results of previous studies, patients with ALK-negative ALCL had a poorer 
outcome than patients with ALK-positive ALCL (3-y OS: 52%, 95% CI: 36-68% vs. 80%, 95% CI: 
60-100%; log-rank, p=0.156). Patients with systemic DUSP22-rearranged ALCL showed better 
OS rates than the triple-negative ALCL genetic subtype (3-y OS: 100% vs. 28%, 96% CI: 4-72%; 
log-rank p=0.05, for triple-negative patients), and similar to ALK-positive ALCL patients (3-y OS: 
80%, 96% CI: 60-100%; log-rank, p=0.422) (Figure 1). 
As previously described(6), DUSP22-rearranged ALCLs showed unusual histological features 
that were consistent among all cases. In the systemic cases, lymph node architecture was 
effaced, with neoplastic infiltration by intermediate cells that were smaller than those 
observed in triple-negative and ALK-positive ALCLs, with a sheet-like growth pattern, and a 
monomorphic appearance. Histopathological findings were consistent among all cases. 
Neoplastic cells exhibited prominent nucleoli and pseudo-inclusions in the so-called 
“doughnut” cells, although they were not specific to this group. Hallmark cells, mitotic figures 
and apoptotic bodies were abundant. Tumor cells were predominant, with no 
lymphohistiocytic or inflammatory background infiltrate. No sinusoidal involvement was 
observed, in contrast to the pattern commonly observed in ALK-positive ALCLs (Figure 2). 
Triple-negative ALCL cases had a more variable morphology, with the presence of hallmark 
cells and large pleomorphic and multinucleated cells. 
The two pcALCL cases with DUSP22 rearrangements had a biphasic pattern, as previously 
reported by our group(7). A prominent dermal nodule with a dense lymphoid infiltrate and 
overlying ulceration was noted at low magnification. The neoplastic infiltrate was composed of 
medium-to-large atypical cells, with abundant finely granular cytoplasm, intermingled with 
abundant hallmark cells. A characteristic pagetoid reticulosis-like intraepidermal lymphocytosis 
pattern was also present, along with intraepidermal small atypical lymphocytes featuring 
hyperchromatic and irregular nuclei. Mitotic figures and apoptotic bodies were abundant 
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within the dermal infiltrate. Eosinophils and neutrophils were absent (Figure 3). 
Among DUSP22-rearranged cases, neoplastic cells were positive in all cases for at least one T-
cell antigen (Table 1), CD3 and/or the T-cell receptor (TCR) β chain (TCRβF1), negative for ALK, 
and strongly and diffusely positive for CD30. TCRβF1 stain was not available in case 2, but CD3 
was positive. Case 5 was CD3-negative but TCRβF1-positive. These markers accentuated the 
sheet-like growth pattern in the systemic cases, and the epidermotropic pagetoid reticulosis-
like infiltrate in the primary cutaneous cases. All cases had a non-cytotoxic phenotype. TIA-1 
was negative in all cases, being found in 5-25% of the tumoral cells. Granzyme B and perforin 
were also negative in all cases (<5% of tumoral cells). MUM1 was positive in four cases 
(median expression in 95% of tumoral cells, range: 75-100%), and only case 6 was completely 
negative. P63 expression was more variable, being positive in 2/5 cases tested (85-100% of 
tumoral cells), and negative (<15% of tumoral cells) in 3/5 cases. The three surrogate markers 
of the JAK/STAT pathway (phosphorylated STAT1, STAT3 and STAT5) were consistently 
negative in all six cases (expression in <20% of tumoral cells). 
In this study, we report six cases of DUSP22-rearranged ALCL (systemic and cutaneous) with 
common histological features, with the presence of intermediate cells with a doughnut-like 
morphology, and abundant hallmark cells, apoptotic and mitotic figures, as previously 
reported(6). In addition, both primary cutaneous cases exhibited a biphasic pattern (7, 8), 
which has also been described in lymphomatoid papulosis cases carrying the same 
translocation(8).  
Furthermore, our results support results recently published by other groups (9), identifying 
lack of activation of the JAK/STAT pathway in DUSP22-rearranged cases, despite initially 
proposed to be a universal finding in ALK-positive and ALK-negative ALCLs (10). 
We describe histological and immunophenotypic features that may help recognize DUSP22-
rearranged cases. The presence of sheets of intermediate-to-large cells, with relatively 
monomorphous large-cell cytology, including hallmark and doughnut cytology, with no 
expression of cytotoxic markers, is useful for further FISH testing in systemic cases. In the 
pcALCL cases, the presence of the previously described biphasic pattern is a useful indicator of 
DUSP22-rearrangement. The same translocation involving locus 6p25 was also described in 
lymphomatoid papulosis (LyP)(8, 11), suggesting that this molecular alteration could determine 
a better outcome, both in cutaneous and systemic ALK-negative ALCL. 
Constant expression of T-cell markers and a lack of cytotoxic markers and markers of activation 
of the STAT pathways seem to be linked to DUSP22 translocation in this series. 
It would be of interest to explore whether this combination of markers in other ALK-negative 
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Table 1. Clinical, Histological, Immunophenotypic, and Genetic Features of 6 Patients with DUSP22-
rearranged ALCL 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Clinical presentation 

























Ann-Arbor Stage III IV ------ III ------ ------ 
ECOG Status 0-1 0-1 ------ ------ ------ ------ 
IPI 
Low-
intermediate ------ ------ Low ------ ------ 
PIT 
Group 1 
(PIT=0) ------ ------ ------ ------ ------ 
Extranodal involvement 
Pleural 
effusion Skin ------ Tonsil ------ ------ 























































































































ALK Negative Negative Negative Negative Negative Negative 
CD3 Positive Positive Positive Positive Negative Positive 
CD30 Positive Positive Positive Positive Positive Positive 
TCRβF1 Positive ------ Positive Positive Positive Positive 
TIA-1 Negative Negative Negative Negative Negative Negative 
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(10%) (15%) (25%) (5%) (10%) (5%) 








































































STAT3 ------ Negative 
(15%) 
------ ------ ------ ------ 
Cytotoxic phenotype Absent Absent Absent Absent Absent Absent 
Follow-up 
Treatment CHOP RT ------ CHOEP Excision Excision 
Treatment response CR CR CR CR ------ ------ 
Recurrence/Progression No Yes (skin) No No No No 
SCT No No No No No No 
Status at last follow-up NED NED NED NED NED NED 
Months since onset 68 66 43 7 1423 12 
Months disease-free 68 9 43 7 1423 12 
 
pcALCL: Primary cutaneous ALCL; M: Male; F: Female; CHOP: Cyclophosphamide + hydroxydaunorubicin + vincristine prednisone; RT: 
Radiotherapy; CHOEP: Cyclophosphamide + hydroxydaunorubicin + vincristine + etoposide + prednisone; RT: Radiotherapy; SCT: Stem-




Figure 1. Outcome in patients with ALCL based on genetic subtype. (A) OS rates in patients 
with ALCL, stratified by ALK status. (B) OS rates in patients with systemic ALK-negative ALCL, 
stratified by rearrangements. (C) OS rates in patients with ALK-positive ALCL and DUSP22-
rearranged ALCL. 
 
Figure 2. Histological and immunophenotypic features of systemic ALK-negative anaplastic 
large cell lymphoma with DUSP22 rearrangement (case 1). (A) Low-power microscopic image 
of a lymph node with effaced architecture. (B) Sheets of medium-to-large neoplastic cells (C) 
with abundant hallmark cells, apoptotic cells and doughnut cells (inset), with an eosinophilic 
nuclear inclusion (D, E and F). Neoplastic cells were diffusely positive for CD3 (G), TCRβF1 (H), 
and CD30 (I), and negative for ALK (J), cytotoxic markers TIA-1 (K), granzyme B (L) and perforin 
(M), and for p-STAT3 (N). (O) FISH using a break-apart probe at the DUSP22 locus shows a 
rearrangement, with one normal fusion signal and an abnormal split signal. 
 
Figure 3. Histological and immunophenotypic features of a primary cutaneous anaplastic 
large cell lymphoma with DUSP22 rearrangement (case 5). (A) Low-power microscopic image 
of the skin biopsy showing diffuse dermal infiltration, characterized histologically by a dense 
dermal infiltrate with epidermal involvement by small lymphocytes (B, C). (D) Dermal infiltrate 
of medium-sized and atypical lymphocytes, with a monomorphic appearance, including 
hallmark and occasional doughnut cells (E, inset; F, inset). Neoplastic cells were CD3-negative 
(G), TCRβF1-positive (H), and CD30-positive (I). ALK (J), TIA-1 (K), granzyme B (L), and perforin 
(M), and P-STAT3 (N) were negative. (O) FISH using a break-apart probe at the DUSP22 locus 






Immunohistochemistry was performed on 3-µm paraffin sections using the Envision method 
(Dako, Glostrup, Denmark) on an automated immunostainer (Dako), using a panel of 
antibodies against ALK (ALK-1, RTU; Dako), CD3 (rabbit polyclonal, RTU; Dako), CD4 (4B12, 
RTU; Dako), CD8 (C8/144B, RTU; Dako), CD30 (Ber-H2, RTU; Dako), granzyme B (GRB7, 1/25, 
Dako), MUM1 (RTU, Dako), perforin (5B10, 1/10, Thermo Fisher Scientific), P-STAT3 (D3A7, 
1/400 Cell Signaling), TIA1 (TA-1, 1/50, Abcam), P-STAT5 (D2A37, 1/200, Cell Signaling), TCR-
βF1 (8A3, 1/40 dilution; Thermo Scientific), P63 (RTU, Dako), STAT3 (F-2, 1/100, Santa Cruz 
Biotechnology) 
Cytotoxic markers were evaluated by measuring the percentage of positive tumoral cells, 
taking 25% of positive neoplastic cells to be the threshold. A cytotoxic phenotype was ascribed 
when two of the three cytotoxic markers were positive, or when only one of them was positive 
in >75% of tumoral cells. MUM 1 was considered positive when expressed in >25% of tumoral 
cells(1); the cut-off value for p63 positivity was 30%, as proposed by another group(2). 
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